Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients

Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients
Trovagene will soon begin patient recruitment for its Phase 2 clinical trial evaluating PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). The study (NCT03414034) will enroll patients at Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital, the three centers where the trial will

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. wangon says:

    After take Abirapro, I have had lots of energy and felt good until recently. My PSA initially went from 66 to 0.1, after 20 months it has started to rise, now it is 0.8 The medicine was easy to take

Leave a Comment

Your email address will not be published. Required fields are marked *